Washington University/Siteman Cancer Center Lead Academic Site

华盛顿大学/斯特曼癌症中心领导学术网站

• 批准号: 10584461
• 负责人: NANCY L BARTLETT
• 金额: $ 130.71万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-05 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10584461
• 关键词: Acute leukemia; Address; American College of Radiology Imaging Network; Area; Cancer Center; Cancer Control; Clinical Research; Clinical Trials; Collaborations; Communication; Comprehensive Cancer Center; Cooperative Group Program; Correlative Study; Data; Development; Disease; Eastern Cooperative Oncology Group; Faculty; Fostering; Genomics; Goals; Gynecologic Oncology; Illinois; Image; Institution; Investments; Lead; Leadership; Lymphoma; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of ovary; Medical Oncology; Mentors; Mentorship; Mission; Missouri; Modality; Molecular; Oncology; Pathology; Patients; Physicians; Play; Positioning Attribute; Principal Investigator; Prognostic Marker; Protocols documentation; Quality of life; Radiation Oncology; Radiology Specialty; Recording of previous events; Rectal Cancer; Reporting; Research Personnel; Resistance; Site; Specialist; Therapeutic; Therapeutic Trials; Thoracic Oncology; Translational Research; Universities; Uterine Cancer; Washington; anticancer research; base; biobank; cancer therapy; control trial; design; diagnostic tool; experience; imaging program; imaging study; improved; malignant breast neoplasm; member; metropolitan; mid-career faculty; molecular imaging; novel; operation; predictive marker; professor; programs; proteogenomics; rare cancer; response; sarcoma; translational scientist

Project Summary The fundamental goal of the proposed Washington University/Siteman Cancer Center (WU/SCC) NCTN Lead Academic Participating Site UG1 is to 1) foster scientific leadership and mentorship in the NCTN, 2) participate in the development of NCTN therapeutic, correlative, and cancer control trials, and 3) maintain strong accrual to clinical trials across multiple disease sites, including those that are molecularly driven and those for rare cancers. WU/SCC investigators have a long history of enthusiastic participation in the former cooperative group program and continue to play key roles in the current NCTN program, specifically the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology. WU/SCC will have 5 UG1 co-Principal Investigators comprising the senior leadership team including Nancy L. Bartlett, MD (Professor, Medical Oncology), Benjamin Kozower, MD, MPH (Professor, Thoracic Oncology), David G. Mutch, MD (Professor, Gynecologic Oncology), Clifford Robinson, MD (Associate Professor, Radiation Oncology) and Barry A. Siegel, MD (Professor, Radiology). The WU/SCC senior leadership team is composed of three legacy members with extensive cooperative group and NCTN experience (Bartlett, Mutch and Siegel) and two new members (Robinson and Kozower) with experience in NCTN trial development. The entire leadership team is committed to providing guidance for an institution-wide NCTN UG1. WU/SCC has consistently demonstrated robust accrual to NCTN trials, accruing 848 patients between March 2014 and August 2017. During this same interval, 535 patients had biospecimens collected and 58 patients were accrued to advanced imaging studies. The strength of the WU/SCC genomics, proteogenomics, and molecular imaging programs in combination with the large institutional biorepositories position us to make significant and novel contributions to the scientific mission of the NCTN. WU/SCC investigators remain highly invested in NCTN translational and clinical research in AML, lymphoma, lung cancer, breast cancer, sarcoma, uterine cancer, molecular imaging, and radiation oncology. In addition, our large referral base and the substantial increase in new cancer cases seen at our center in the last 5 years will enhance our ability to accrue patients to nearly all disease site protocols, including rare tumors. This institution-wide UG1 will facilitate enhanced communication and collaboration among disease-site, translational, and modality specialists and improve our potential for contributions to the NCTN operation.

项目概要 拟议的华盛顿大学/斯特曼癌症中心的基本目标 (WU/SCC) NCTN 主导学术参与站点 UG1 旨在 1) 培养科学领导力和 NCTN 的指导，2) 参与 NCTN 治疗、相关、 和癌症控制试验，以及 3) 保持多种疾病临床试验的强劲收益 站点，包括分子驱动的站点和罕见癌症的站点。吴/SCC 调查人员长期以来对前合作组的热情参与 计划并继续在当前的 NCTN 计划中发挥关键作用，特别是联盟 用于肿瘤学临床试验、ECOG-ACRIN 癌症研究组和 NRG 肿瘤学。 WU/SCC 将有 5 名 UG1 联合首席研究员组成高级领导团队 包括 Nancy L. Bartlett，医学博士（肿瘤内科教授）、Benjamin Kozower，医学博士、公共卫生硕士 （胸部肿瘤学教授），David G. Mutch，医学博士（妇科肿瘤学教授）， Clifford Robinson，医学博士（放射肿瘤学副教授）和 Barry A. Siegel，医学博士 （放射学教授）。 WU/SCC 高级领导团队由三名传统人士组成 具有广泛合作团体和NCTN经验的成员（Bartlett、Mutch和Siegel） 以及两名具有 NCTN 试验开发经验的新成员（Robinson 和 Kozower）。 整个领导团队致力于为全机构范围内的 NCTN 提供指导 UG1。 WU/SCC 一贯表现出对 NCTN 试验的强劲增长，累计 848 2014 年 3 月至 2017 年 8 月期间，有 535 名患者接受过治疗。 收集了生物样本，并对 58 名患者进行了高级成像研究。这 WU/SCC 基因组学、蛋白质组学和分子成像项目的实力 与大型机构生物样本库的结合使我们能够做出重要且新颖的研究 为 NCTN 的科学使命做出贡献。 WU/SCC 调查人员仍然高度重视 投资NCTN AML、淋巴瘤、肺癌、乳腺癌的转化和临床研究 癌症、肉​​瘤、子宫癌、分子成像和放射肿瘤学。此外，我们的 庞大的转诊基数以及我们中心的新癌症病例大幅增加 过去 5 年将增强我们让患者参与几乎所有疾病现场方案的能力， 包括罕见的肿瘤。这个机构范围内的 UG1 将促进加强沟通和 疾病现场、转化和模式专家之间的合作，并改善我们的 对 NCTN 运营做出贡献的潜力。